Cerebrospinal Fluid Kinetics of Urolithin A (NCT07517913) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Cerebrospinal Fluid Kinetics of Urolithin A
India40 participantsStarted 2026-05-01
Plain-language summary
The purpose of this study is to determine the impact of MitopureĀ® consumption on urolithin A (UA) kinetics in cerebral spinal fluid (CSF).
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* 1\. Healthy male and female participants aged between 18 and 45 years (both inclusive);
* 2\. Non-smoker subject or smoker of not more than 5 cigarettes a day;
* 3\. Body Mass Index (BMI) between 18.50-30.00 kg/m2 inclusive;
* 4\. Trial participants in normal health as determined by personal medical history, clinical examination including vital signs, and clinically acceptable results of laboratory examinations (including serological tests), individual values out of the normal range can be accepted if judged clinically non relevant by the Investigator;
* 5\. Normal electrocardiogram (ECG) recording on a 12-lead ECG and/or chest X-ray (PA view) significant at the screening visit or considered not clinically significant (NCS) by investigators;
* 6\. A negative alcohol breath test result at housing;
* 7\. Trial participant able to communicate effectively, provide voluntary written informed consent and available for the entire study duration;
* 8\. Trial participants willing to adhere to the protocol requirements as evidenced by written informed consent approved by the ethics committee;
* 9\. Ability to fast for at least 14.00 hours and consume standard meals;
* 10\. Accept to refrain consuming certain foods and supplements at least two weeks before inclusion;
* 11\. Female participants must have a negative urine pregnancy test prior to housing;
* 12\. Trial participants that can provide adequate evidence of their identity;
* 13\. The participants agree to ā¦